Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2276 August 2025

| APPLICANT (stamp or sticker acceptable) | PATIENT NHI: | REFERRER Reg No: |
|---|---|---|
| Reg No: | First Names: | First Names: |
| Name: | Surname: | Surname: |
| Address: | DOB: | Address: |
| | Address: | |
| | | |
| Fax Number: | | Fax Number: |
| Pertuzumab | | |
| Initial application — metastatic breast cancer Applications from any relevant practitioner. Approvals valid for 12 months. Prerequisites(tick boxes where appropriate) The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology) Patient is chemotherapy treatment naïve or Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer and The patient has good performance status (ECOG grade 0-1) and Pertuzumab to be administered in combination with trastuzumab and Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks Pertuzumab to be discontinued at disease progression | | |
| Renewal — metastatic breast cancer | | |
| Current approval Number (if known): | | |
| Prerequisites(tick boxes where appropriate) | | |
| and | reast cancer expressing HER-2 IHC 3+ or ISH+ (incl | |
| or | | |
| Patient has previously discor disease progression | ntinued treatment with pertuzumab and trastuzumab | for reasons other than severe toxicity or |
| Patient has signs of disease | progression | |
| | during previous treatment with pertuzumab and trast | uzumab |

I confirm the above details are correct and that in signing this form I understand I may be audited.